Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Recurrence 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma 1

Interventions

Temozolomide 69Bevacizumab 40Radiotherapy 22Magnetic Resonance Spectroscopy 20Irinotecan 17Specimen Handling 10Carboplatin 10Carmustine 9X-Rays 7Radiation 7olaparib 6Surgical Procedures, Operative 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Nivolumab 6Everolimus 6Cyclophosphamide 6Biopsy 6trametinib 5Thalidomide 5Cisplatin 5pembrolizumab 4palbociclib 4fluorodopa F 18 4erdafitinib 4dabrafenib 4Lomustine 4Etoposide 4Drug Therapy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Glioma × rilotumumab × Clear all
NCT01113398 2015-12-10

AMG 102 and Avastin for Recurrent Malignant Glioma

Duke University

Phase 2 Completed
36 enrolled 9 charts
CNSSarcoma

Glioblastoma, Glioma, Recurrence, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡